Premium
Adult acute lymphoblastic leukemia
Author(s) -
Faderl Stefan,
O'Brien Susan,
Pui ChingHon,
Stock Wendy,
Wetzler Meir,
Hoelzer Dieter,
Kantarjian Hagop M.
Publication year - 2010
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.24862
Subject(s) - medicine , minimal residual disease , lymphoblastic leukemia , disease , risk stratification , intensive care medicine , cancer , blood cancer , leukemia , oncology , immunology
Acute lymphoblastic leukemia (ALL), a clonal expansion of hematopoietic blasts, is a highly heterogeneous disease comprising many entities for which distinct treatment strategies are pursued. Although ALL is a success story in pediatric oncology, results in adults lag behind those in children. An expansion of new drugs, more reliable immunologic and molecular techniques for the assessment of minimal residual disease, and efforts at more precise risk stratification are generating new aspects of adult ALL therapy. For this review, the authors summarized pertinent and recent literature on ALL biology and therapy, and they discuss current strategies and potential implications of novel approaches to the management of adult ALL. Cancer 2010. © 2010 American Cancer Society.